These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 33831618)
1. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). Bonadonna P; Brockow K; Niedoszytko M; Elberink HO; Akin C; Nedoszytko B; Butterfield JH; Alvarez-Twose I; Sotlar K; Schwaab J; Jawhar M; Castells M; Sperr WR; Hermine O; Gotlib J; Zanotti R; Reiter A; Broesby-Olsen S; Bindslev-Jensen C; Schwartz LB; Horny HP; Radia D; Triggiani M; Sabato V; Carter MC; Siebenhaar F; Orfao A; Grattan C; Metcalfe DD; Arock M; Gulen T; Hartmann K; Valent P J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2139-2144. PubMed ID: 33831618 [TBL] [Abstract][Full Text] [Related]
2. Safety of COVID-19 mRNA vaccination and effects of SARS-CoV-2 infection in children and adults with mast cell disorders. Zhu CK; Nguyen A; Prosty C; Gabrielli S; Mulé P; Netchiporouk E; Le M; Zhang X; Shand G; Baum S; Hakroush R; Greenberger S; Ollech A; Miedzybrodzki B; Ben-Shoshan M Clin Exp Med; 2023 Dec; 23(8):4937-4942. PubMed ID: 37837561 [TBL] [Abstract][Full Text] [Related]
3. New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. Arock M; Sotlar K; Gotlib J; Sperr WR; Hartmann K; Schwartz LB; Akin C; Horny HP; Valent P Leuk Lymphoma; 2020 May; 61(5):1075-1083. PubMed ID: 31876203 [TBL] [Abstract][Full Text] [Related]
4. Anaphylaxis is a rare reaction in COVID-19 vaccination. Bellomo RG; Gallenga CE; Caraffa A; Tetè G; Ronconi G; Conti P J Biol Regul Homeost Agents; 2021; 35(3):839-842. PubMed ID: 34105336 [TBL] [Abstract][Full Text] [Related]
5. Latent Mastocytosis Triggered by COVID-19 Vaccination: A Case Report. Calogiuri G; Foti C; Congedo M; Nettis E; Paladini L; Greco G; Pavone V; Vacca A Endocr Metab Immune Disord Drug Targets; 2024; 24(4):495-498. PubMed ID: 37817657 [TBL] [Abstract][Full Text] [Related]
6. Mast Cell Disorders In Drug Hypersensitivity. Bonadonna P; Bonifacio M; Zanotti R Curr Pharm Des; 2016; 22(45):6862-6869. PubMed ID: 27779084 [TBL] [Abstract][Full Text] [Related]
7. Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders? Azenha Rama T; Álvarez-Twose I J Investig Allergol Clin Immunol; 2021 Apr; 31(2):193-195. PubMed ID: 33574015 [No Abstract] [Full Text] [Related]
8. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. Kaakati R; Khokhar D; Akin C J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3198-3199. PubMed ID: 34033981 [No Abstract] [Full Text] [Related]
9. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. Gotlib J; George TI; Carter MC; Austen KF; Bochner B; Dwyer DF; Lyons JJ; Hamilton MJ; Butterfield J; Bonadonna P; Weiler C; Galli SJ; Schwartz LB; Elberink HO; Maitland A; Theoharides T; Ustun C; Horny HP; Orfao A; Deininger M; Radia D; Jawhar M; Kluin-Nelemans H; Metcalfe DD; Arock M; Sperr WR; Valent P; Castells M; Akin C J Allergy Clin Immunol; 2021 Jun; 147(6):2043-2052. PubMed ID: 33745886 [TBL] [Abstract][Full Text] [Related]
10. Low Frequency of IgE-Mediated Food Hypersensitivity in Mastocytosis. Jarkvist J; Brockow K; Gülen T J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3093-3101. PubMed ID: 32534147 [TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
12. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives. Valent P; Hartmann K; Bonadonna P; Sperr WR; Niedoszytko M; Hermine O; Kluin-Nelemans HC; Sotlar K; Hoermann G; Nedoszytko B; Broesby-Olsen S; Zanotti R; Lange M; Doubek M; Brockow K; Alvarez-Twose I; Varkonyi J; Yavuz S; Nilsson G; Radia D; Grattan C; Schwaab J; Gülen T; Oude Elberink HNG; Hägglund H; Siebenhaar F; Hadzijusufovic E; Sabato V; Mayer J; Reiter A; Orfao A; Horny HP; Triggiani M; Arock M J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1706-1717. PubMed ID: 36868470 [TBL] [Abstract][Full Text] [Related]
13. COVID-19 Vaccination Safety and Tolerability in Patients Allegedly at High Risk for Immediate Hypersensitivity Reactions. Ieven T; Vandebotermet M; Nuyttens L; Devolder D; Vandenberghe P; Bullens D; Schrijvers R Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214744 [TBL] [Abstract][Full Text] [Related]
14. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis. Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948 [TBL] [Abstract][Full Text] [Related]
15. Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. Rossignol J; Ouedrani A; Livideanu CB; Barete S; Terriou L; Launay D; Lemal R; Greco C; Frenzel L; Meni C; Bodemere-Skandalis C; Polivka L; Collange AF; Hachichi H; Bouzourine S; Messaoud DN; Negretto M; Vendrame L; Jambou M; Gousseff M; Durupt S; Lega JC; Durand JM; Gaudy C; Damaj G; Gourin MP; Hamidou M; Bouillet L; Le Mouel E; Maria A; Zunic P; Cabrera Q; Vincent D; Lavigne C; Riviere E; Gourguechon C; Courbebaisse M; Lebeaux D; Parfait B; Friedlander G; Brignier A; Lhermitte L; Molina TJ; Bruneau J; Agopian J; Dubreuil P; Ranta D; Mania A; Arock M; Staropoli I; Tournilhac O; Lortholary O; Schwartz O; Chatenoud L; Hermine O J Allergy Clin Immunol Pract; 2022 May; 10(5):1356-1364.e2. PubMed ID: 35074600 [TBL] [Abstract][Full Text] [Related]
16. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. Rama TA; Moreira A; Castells M J Allergy Clin Immunol; 2021 Mar; 147(3):877-878. PubMed ID: 33485650 [No Abstract] [Full Text] [Related]
18. Epidemiology, prognosis, and risk factors in mastocytosis. Brockow K Immunol Allergy Clin North Am; 2014 May; 34(2):283-95. PubMed ID: 24745674 [TBL] [Abstract][Full Text] [Related]
19. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy. Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980 [TBL] [Abstract][Full Text] [Related]
20. Drug allergy in mastocytosis. Bonadonna P; Lombardo C Immunol Allergy Clin North Am; 2014 May; 34(2):397-405. PubMed ID: 24745682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]